ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: SA-PO645

Cell-Surface Glycoprofiling of IgA1-Secreting Cells From Patients With IgA Nephropathy Reveals Subpopulations With Differential Cytokine Responses and Capacity to Produce Galactose-Deficient IgA1

Session Information

Category: Glomerular Diseases

  • 1302 Glomerular Diseases: Immunology and Inflammation


  • Reily, Colin, The University of Alabama at Birmingham College of Arts and Sciences, Birmingham, Alabama, United States
  • Nakazawa, Shigeaki, Osaka Daigaku Daigakuin Igakukei Kenkyuka Igakubu Igaku Senko, Suita, Osaka, Japan
  • Julian, Bruce A., The University of Alabama at Birmingham College of Arts and Sciences, Birmingham, Alabama, United States
  • Novak, Jan, The University of Alabama at Birmingham College of Arts and Sciences, Birmingham, Alabama, United States

Galactose-deficient IgA1 (Gd-IgA1) is the main autoantigen in IgA nephropathy (IgAN) and its elevated circulatory levels predict poor kidney outcome. As Gd-IgA1 constitutes a small fraction of total circulatory IgA1, we hypothesize that only a few IgA1-secreting cells may be involved. Moreover, cytokine stimulation can increase Gd-IgA1 production in cultured IgA1-producing cells from IgAN patients. We report here that cell-surface glycoprofiling of immortalized IgA1+ cells with a GalNAc-Gal-specific lectin (peanut agglutinin, PNA) can identify subsets of cells with differential signaling and O-glycosylation of IgA1.


Immortalized IgA1-producing cells derived from peripheral blood mononuclear cells of healthy controls (HC) and IgAN patients were stimulated with mixture of cytokines (IL-4, IL-6, IL-21, CD40L) for 20 min, followed by cell-surface staining with PNA and IgA-specific antibody and FACS. Non-stimulated cells served as negative controls. The live-sorted cells with distinct PNA binding (low- and high-PNA-binding cells) were cultured and assessed for baseline and cytokine-mediated signaling and Gd-IgA1 production. Gd-IgA1 was determined by lectin ELISA, phosphoproteins by intracellular staining with antibodies and FACS.


For both HC- and IgAN-derived IgA1+ cells without cytokine stimulation (i.e., baseline), high-PNA-binding cells exhibited more phosphorylated (P) ERK1/2, less P-65-NF-kB, and less P-STAT1 compared to low-PNA-binding cells (p<0.01, p=0.02, p<0.01, respectively). Moreover, there was less P-65-NF-kB in HC- vs. IgAN-derived cells, but only for the low-PNA-binding cells (p=0.01). For both HC- and IgAN-derived IgA1+ cells with cytokine stimulation, P-ERK1/2 was increased in PNA-high cells (p<0.01) and P-65-NF-kB was increased in PNA-low cells (p=0.01). In a pilot experiment, the high-PNA-binding cells from an IgAN patient produced more Gd-IgA1 compared to low-PNA-binding cells.


Glycoprofiling of IgA1+ cells with PNA lectin revealed cells with differential cell-surface glycosylation. These distinct cell types differed in baseline and cytokine-induced cell signaling and Gd-IgA1 production.


  • NIDDK Support